Related Experiment Video

Updated: May 9, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
03:23

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Protection of montelukast on OVA-induced eosinophilic gastroenteritis via modulating IL-5, eotaxin-1 and MBP

Daihong Wan1, Xiaohui Zhang, Xuemei Liu

  • 1Provincial Hospital Affiliated to Shandong University , Jinan 250014 , PR China and.

Immunopharmacology and Immunotoxicology
|July 17, 2013
PubMed

Insights

Montelukast treatment reduced key inflammatory markers, including eotaxin-1 and interleukin-5, in a mouse model of eosinophilic gastroenteritis. The drug also attenuated major basic protein expression in jejunal tissue, suggesting therapeutic potential.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Eosinophilic gastroenteritis is an inflammatory condition characterized by eosinophil infiltration of the gastrointestinal tract.
  • Ovalbumin-induced models in mice are commonly used to study the pathogenesis and potential treatments for eosinophilic gastroenteritis.
  • Montelukast, a leukotriene receptor antagonist, is used for asthma and allergic rhinitis, but its role in eosinophilic gastroenteritis requires further investigation.

Purpose of the Study:

  • To investigate the therapeutic mechanisms of montelukast in a mouse model of oral ovalbumin-induced eosinophilic gastroenteritis.
  • To evaluate the effects of montelukast on specific inflammatory mediators and cellular markers in the intestinal mucosa.

Main Methods:

  • A mouse model was established by oral administration of ovalbumin.
  • Mice were treated with montelukast.
  • Levels of eotaxin-1 and interleukin-5 in intestinal mucosa homogenates were measured.
  • Expression of major basic protein in jejunal tissue was assessed.

Main Results:

  • Montelukast treatment significantly prevented elevated levels of eotaxin-1 and interleukin-5 in the intestinal mucosa compared to the model group.
  • The increase in major basic protein expression in jejunal tissue was also significantly attenuated in mice treated with montelukast.

Conclusions:

  • Montelukast demonstrates potential therapeutic effects against eosinophilic gastroenteritis in a mouse model.
  • The drug appears to modulate key inflammatory pathways involving eotaxin-1, interleukin-5, and major basic protein.
  • Further research into montelukast as a treatment for eosinophilic gastroenteritis is warranted.

More Related Videos

Murine Model of Allergen Induced Asthma08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...